/

PPCB

Propanc Biopharma, Inc.Closed

0.4125−0.03 −6.25%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.4100 −0.61%

Open

0.4284

Prev close

0.4400

Day range

0.41000.4441

52-week range

0.410047.50

Volume

332.17K0.18×

Mkt cap

4.06M

P/E ttm

—

Fwd P/E

—

EPS ttm

-17.62

Div yield

0.00%

Earnings

—

From 52w high

−99.13%

Price Chart

Yahoo Finance · delayed

PPCBOct 13, 2026O 0.4284H 0.4441L 0.4100C 0.4125−0.0275 (−6.25%)Vol 333.40K

SMA 500.9050
SMA 2003.1598

1Y change −99.10% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PPCB Propanc Biopharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −16.04%
1 month: −55.21%
3 months: −74.69%
6 months: −83.08%
Year to date: −96.93%
1 year: −99.10%

Valuation & ownership

Market cap: 4.06M
Enterprise value: 2.29M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: 0.15
Price / sales (ttm): —
EV / EBITDA: -0.13
EPS (ttm): -17.62
EPS (forward): —
Beta (5y monthly): 3.33
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 9.83M
Float: 5.40M
Short % of float: 1.17%
Short ratio (days): 0.21
Held by insiders: 62.21%
Held by institutions: 0.76%
Avg volume (3m): 1.82M
50-day average: 0.9178
200-day average: 3.24
52-week change: −99.10%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 29.7
vs 50-day SMA: −54.42%
vs 200-day SMA: −86.95%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 23.09%
Realised vol (20d, ann.): 115.3%
From 52-week high: −99.13%
From 52-week low: +0.61%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Propanc Biopharma, Inc.

Yahoo Finance profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Sector: Healthcare
Industry: Biotechnology
Employees: 2
Headquarters: Camberwell, VIC, Australia
Website: propanc.com
Officers: Mr. James Nathanielsz CEO & Executive Chairman
Ms. Jeannine Zimmerman Chief Financial Officer
Prof. Klaus Kutz M.D. Acting Chief Medical Officer & Member of Scientific Advisory Board

SEAS

Seasonality · PPCB

2013–2026 · monthly returns

Strongest month Jan +208340.74%Weakest month Sep −27.17%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-57.5	-15.3	-45.1	-4.2	-28.3	-17.6	-32.7	33.7	-63.4	-16.5			−96.9%
2025	2499900.1	-32.5	-18.5	-45.3	-25.2	84.4	140.7	-69.8	-43.7	-27.1	-27.9	-40.0	+134050.0%
2024	-50.0	-43.3	-5.9	-68.7	90.0	-31.6	-38.5	-50.0	-25.0	0.0	0.0	-33.3	−98.3%
2023	-33.3	75.0	-28.6	-40.0	-83.5	172.7	-45.9	-24.9	-55.6	-53.3	-25.4	41.2	−98.0%
2022	-56.1	-12.4	-7.7	-28.2	-32.1	-51.3	-10.8	-42.4	-36.8	-16.7	-30.0	-14.3	−98.6%
2021	82.1	-48.0	-2.5	-11.5	-65.1	-35.4	-30.6	31.8	-45.0	12.3	-31.5	120.0	−84.3%
2020	-58.8	-63.0	-48.1	-57.1	-13.2	-65.2	-48.7	20.0	-20.8	0.0	-57.9	-65.0	−99.9%
2019	-8.8	-17.6	-26.2	-23.4	-3.7	51.9	-71.7	-28.4	-33.5	-19.8	-50.4	17.8	−96.1%
2018	0.0	-25.0	-9.5	-17.4	-21.0	-11.3	-55.5	218.4	9.0	-41.2	-48.0	-25.8	−86.2%
2017	22.1	1.0	-14.2	-13.4	-29.2	-30.5	-56.7	-25.0	3.1	-66.1	0.0	27.3	−93.5%
2016	-28.3	-46.5	184.1	18.4	-36.1	-18.7	-5.3	-15.3	-8.0	-9.4	-18.4	-15.7	−69.2%
2015	320.0	-47.6	354.5	86.7	103.6	57.7	-50.9	-10.4	-26.8	24.2	9.7	-29.2	+1760.0%
2014	0.0	0.0	0.0	0.0	190.0	-70.3	4.4	-44.4	-70.0	-70.0	-33.3	-50.0	−98.5%
2013		0.0	33.3	0.0	-55.0	-55.6	0.0	0.0	0.0	-50.0	0.0	0.0	−86.7%

PPCB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PPCB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Propanc Biopharma, Inc.

Seasonality · PPCB

Insider Activity · PPCB

Congress Trades · PPCB

Investors Holding PPCB

Investors Holding PPCB

Congress Trades · PPCB

Insider Activity · PPCB

Seasonality · PPCB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Propanc Biopharma, Inc.

Earnings & Dividends

News